Related Experiment Videos
CAMPATH-1H in inflammatory arthritis
R A Watts1, J D Isaacs, G Hale
1Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, U.K.
Clinical and Experimental Rheumatology
|March 1, 1993
Summary
Campath-1H, a monoclonal antibody, shows promise in treating rheumatoid arthritis by improving clinical symptoms for up to 8 months. It induces prolonged lymphopenia, suppressing CD4+ T-cell counts for a year.
Area of Science:
- Immunology
- Rheumatology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
- Existing RA treatments have limitations in efficacy and side effect profiles.
Purpose of the Study:
- To evaluate the efficacy and safety of Campath-1H, a humanized monoclonal antibody, in treating rheumatoid arthritis patients.
Main Methods:
- Campath-1H, a monoclonal antibody targeting lymphocytes, was administered to patients with rheumatoid arthritis.
- Clinical outcomes, including Ritchie index and joint scores, were assessed.
- Lymphocyte subsets, particularly CD4+ T-cells, were monitored for changes.
Main Results:
- Patients experienced clinical improvement, with reduced Ritchie index and joint scores lasting up to 8 months.
- Campath-1H induced profound and prolonged lymphopenia.
- CD4+ T-cell counts remained suppressed for up to one year post-treatment.
Conclusions:
- Campath-1H demonstrates potential as a therapeutic agent for rheumatoid arthritis, offering sustained clinical benefits.
- The immunomodulatory effects, including prolonged lymphopenia, contribute to its therapeutic action in RA.
- Further research is warranted to optimize dosing and long-term safety profiles.